Hemostemix (CVE:HEM) Trading Up 30% – Still a Buy?

Shares of Hemostemix Inc. (CVE:HEM) were up 30% during trading on Tuesday . The stock traded as high as C$0.13 and last traded at C$0.13. Approximately 296,012 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 478,655 shares. The stock had previously closed at C$0.10.

Hemostemix Price Performance

The firm has a market capitalization of C$18.94 million, a P/E ratio of -3.79 and a beta of 0.20. The company has a fifty day moving average of C$0.10 and a 200 day moving average of C$0.14. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.

Insiders Place Their Bets

In other news, Director Peter Alan Lacey bought 200,000 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The shares were bought at an average cost of C$0.15 per share, for a total transaction of C$30,000.00. Company insiders own 10.43% of the company’s stock.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.